In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $65.12, marking a -0.69% move from the previous day. This change was narrower than the S&P 500's 2.08% loss on the day. Meanwhile, the Dow lost 2.11%, and the Nasdaq, a tech-heavy index, lost 2.27%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had lost 6.03% over the past month. This has lagged the Medical sector's loss of 1.48% and the S&P 500's loss of 3.6% in that time.
GILD will be looking to display strength as it nears its next earnings release, which is expected to be February 5, 2019. In that report, analysts expect GILD to post earnings of $1.74 per share. This would mark a year-over-year decline of 2.25%. Our most recent consensus estimate is calling for quarterly revenue of $5.52 billion, down 7.26% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.93 per share and revenue of $21.85 billion. These totals would mark changes of -21.61% and -16.31%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for GILD. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. GILD currently has a Zacks Rank of #1 (Strong Buy).
Looking at its valuation, GILD is holding a Forward P/E ratio of 9.46. Its industry sports an average Forward P/E of 21.68, so we one might conclude that GILD is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 63, which puts it in the top 25% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.